/PRNewswire/ Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the appointment of.
Neurana Pharmaceuticals to Present at 21st Annual Pain Therapeutics Conference
News provided by
Share this article
Share this article
SAN DIEGO, May 11, 2021 /PRNewswire/ Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Randall Kaye, Chief Medical Officer, will present at the 21
st Annual Pain Therapeutics Conference. The conference takes place virtually May 10-11
th. Presentations will be available for registered attendees via the conference website.
About Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana s lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the l